Literature DB >> 32067826

Epidemiology of chronic inflammatory demyelinating polyneuropathy in the South-Eastern area of Santiago, Chile.

Gabriel Cea1, Juan Francisco Idiáquez2, Rodrigo Salinas3, José Manuel Matamala4, Roque Villagra5, Andrés Stuardo6.   

Abstract

Chronic inflammatory demyelinating polyneuropathy (CIDP) is an immune-mediated polyneuropathy. It usually has an insidious onset, progressive course and heterogeneous clinical features. As far as we know, there is no epidemiological information on CIDP in South America and the Caribbean. Our aim was to estimate the frequency of CIDP in the South-Eastern region of Santiago, where our hospital is based and the population number assigned is officially reported every year by the health authorities. Records of 581 patients registered with the diagnosis of neuropathy were found and all patients meeting the diagnostic criteria of the EFNS/PNS for definitive and possible CIDP were included. Data were collected using a data extraction protocol designed by the authors and which included demographic, clinical, laboratory and electrophysiological information. The estimated prevalence and incidence of CIDP were 2.95/100,000 and 0.46/100,000 respectively. Fifteen patients (8 men, 7 women) were classified as definitive or possible CIDP. Nine patients had typical CIDP and three also had diabetes mellitus. The prevalence and incidence rates were similar to those reported in other regions of the world.
Copyright © 2020. Published by Elsevier Ltd.

Entities:  

Keywords:  Chronic inflammatory demyelinating; Incidence; Prevalence

Year:  2020        PMID: 32067826     DOI: 10.1016/j.jocn.2020.02.009

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  1 in total

1.  Epidemiology of chronic inflammatory demyelinating polyradiculoneuropathy in The Netherlands.

Authors:  Merel C Broers; Marcel de Wilde; Hester F Lingsma; Johan van der Lei; Katia M C Verhamme; Bart C Jacobs
Journal:  J Peripher Nerv Syst       Date:  2022-05-29       Impact factor: 5.188

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.